宫颈癌盆腔淋巴结转移生物标志物研究进展

Advances in Biomarkers of Pelvic Lymph Node Metastasis in Cervical Cancer

区域淋巴结扩散是宫颈癌转移的主要途径,淋巴结状态已被纳入国际妇产科联盟(FIGO)最新宫颈癌分期系统。多项研究表明,盆腔淋巴结转移是宫颈癌患者的一个独立预后因素,转移情况决定了宫颈癌的治疗策略。目前,除手术后的组织病理学检查外,术前尚无法准确检测宫颈癌的淋巴结转移情况。宫颈癌盆腔淋巴结转移生物标志物的发现可提高术前淋巴结转移诊断的准确率,有助于筛选高死亡风险的患者,进而提供有效的临床治疗方法。综述以上皮-间质转化(EMT)、血管内皮生长因子C(VEGF-C)和微小RNA(miRNA)为中心的宫颈癌盆腔淋巴结转移相关分子研究进展,发现可能的生物标志物,为术前宫颈癌淋巴结转移的诊断提供参考。

Regional lymph node diffusion is the main route of cervical cancer metastasis.Lymph node status has been included in the latest cervical cancer staging system of the international federation of obstetrics and gynecology(FIGO).Several studies have shown that pelvic lymph node metastasis is an independent prognostic factor for the survival of cervical cancer and determines the treatment strategy of cervical cancer.At present,except for the histopathological examination after surgery,the lymph node metastasis of cervical cancer can not be accurately detected before an operation.The discovery of cervical cancer lymph node metastasis biomarkers can improve the accuracy of preoperative lymph node metastasis diagnosis,help to identify patients with a high risk of death,and then provide effective clinical treatment for cervical cancer.In this review,we summarize the research progress on the molecular mechanism of pelvic lymph node metastasis of cervical cancer centered on epithelial mesenchymal transition(EMT),vascular endothelial growth factor-C(VEGF-C)and microRNA(miRNA)and find the possible biomarkers to provide a reference for preoperative diagnosis of cervical cancer lymph node metastasis.